← Patent-cliff monitor small molecule JASCAYD NERANDOMILAST
Loss of exclusivity October 2038 latest FDA-listed patent expiry
Drug detail Brand name JASCAYD Active ingredient NERANDOMILAST Strength 18MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2025 Marketing status RX
Listed patents Patent Expires Type 11813266 October 2038 use U-4292 11406638 October 2038 use U-4297 9802954 February 2034 use U-4298 8609670 August 2032 substance 8754073 November 2029 substance, product
Regulatory exclusivity Code Expires ODE-546 October 2032 NCE October 2030 I-979 December 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.